Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AORT Artivion	$28.64 +0.6%	$25.13	$21.97 ▼ $32.33	$1.22B	1.54	326,494 shs	241,597 shs
CDRE Cadre	$32.69 -1.3%	$31.31	$27.07 ▼ $40.28	$1.33B	1.34	250,771 shs	298,299 shs
CLPT ClearPoint Neuro	$11.89 -1.6%	$12.80	$5.11 ▼ $19.22	$332.79M	1.03	236,071 shs	172,203 shs
LQDA Liquidia	$15.35 -1.3%	$14.74	$8.26 ▼ $19.41	$1.31B	0.24	1.07 million shs	4.74 million shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AORT Artivion	0.00%	-2.78%	+20.18%	+1.22%	+20.44%
CDRE Cadre	0.00%	-6.95%	+8.93%	-2.95%	+2.48%
CLPT ClearPoint Neuro	0.00%	-9.79%	-16.79%	-28.89%	+96.20%
LQDA Liquidia	0.00%	-18.70%	+9.41%	-4.72%	+16.91%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AORT Artivion	1.5569 of 5 stars	1.6	1.0	0.0	3.4	2.5	1.9
CDRE Cadre	3.6112 of 5 stars	2.5	3.0	2.5	3.4	3.3	1.9
CLPT ClearPoint Neuro	1.6634 of 5 stars	3.5	2.0	0.0	2.2	0.0	0.6
LQDA Liquidia	3.4497 of 5 stars	4.5	0.0	0.0	3.8	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AORT Artivion	3.17	Buy	$31.40	9.64% Upside
CDRE Cadre	3.00	Buy	$37.00	13.18% Upside
CLPT ClearPoint Neuro	3.00	Buy	$25.00	110.26% Upside
LQDA Liquidia	3.00	Buy	$25.56	66.49% Upside

Current Analyst Ratings Breakdown

Latest CLPT, LQDA, CDRE, and AORT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/21/2025	LQDA Liquidia	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00 ➝ $25.00
5/19/2025	LQDA Liquidia	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Market Perform ➝ Underperform	$13.00
5/12/2025	LQDA Liquidia	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00 ➝ $25.00
5/12/2025	LQDA Liquidia	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$29.00 ➝ $29.00
5/9/2025	LQDA Liquidia	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Strong-Buy ➝ Strong-Buy	$27.00 ➝ $29.00
5/6/2025	AORT Artivion	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/6/2025	AORT Artivion	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$33.00 ➝ $33.00
5/6/2025	AORT Artivion	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00
5/5/2025	LQDA Liquidia	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/5/2025	LQDA Liquidia	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$34.00 ➝ $36.00
4/10/2025	LQDA Liquidia	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00 ➝ $25.00

(Data available from 5/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AORT Artivion	$390.08M	3.14	$0.78 per share	36.78	$6.87 per share	4.17
CDRE Cadre	$559.81M	2.37	$1.43 per share	22.89	$5.25 per share	6.23
CLPT ClearPoint Neuro	$32.24M	10.32	N/A	N/A	$0.86 per share	13.83
LQDA Liquidia	$14.14M	92.77	N/A	N/A	$0.73 per share	21.03

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AORT Artivion	-$30.69M	-$0.50	N/A	57.28	N/A	-0.22%	5.15%	1.91%	N/A
CDRE Cadre	$38.64M	$0.95	39.39	24.04	1.58	6.34%	12.88%	6.06%	8/8/2025 (Estimated)
CLPT ClearPoint Neuro	-$22.09M	-$0.76	N/A	N/A	N/A	-59.64%	-62.10%	-38.39%	8/6/2025 (Estimated)
LQDA Liquidia	-$78.50M	-$1.58	N/A	N/A	N/A	-765.38%	-163.21%	-67.14%	8/6/2025 (Estimated)

Latest CLPT, LQDA, CDRE, and AORT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	CLPT ClearPoint Neuro	-$0.15	-$0.22	-$0.07	-$0.22	$8.21 million	$8.49 million
5/8/2025	Q1 2025	LQDA Liquidia	-$0.42	-$0.45	-$0.03	-$0.45	$3.23 million	$3.12 million
5/6/2025	Q1 2025	CDRE Cadre	$0.13	$0.23	+$0.10	$0.23	$121.53 million	$130.11 million
5/5/2025	Q1 2025	AORT Artivion	$0.12	$0.06	-$0.06	-$0.01	$94.81 million	$98.98 million
3/19/2025	Q4 2024	LQDA Liquidia	-$0.38	-$0.46	-$0.08	-$0.46	$4.60 million	$2.92 million
3/11/2025	Q4 2024	CDRE Cadre	$0.48	$0.32	-$0.16	$0.32	$170.95 million	$175.98 million
2/26/2025	Q4 2024	CLPT ClearPoint Neuro	-$0.15	-$0.20	-$0.05	-$0.20	$8.23 million	$7.77 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AORT Artivion	N/A	N/A	N/A	N/A	N/A
CDRE Cadre	$0.38	1.16%	+63.55%	40.00%	2 Years
CLPT ClearPoint Neuro	N/A	N/A	N/A	N/A	N/A
LQDA Liquidia	N/A	N/A	N/A	N/A	N/A

Latest CLPT, LQDA, CDRE, and AORT Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/22/2025	CDRE Cadre	quarterly	$0.0950	1.29%	5/2/2025	5/2/2025	5/16/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AORT Artivion	0.71	1.88	1.33
CDRE Cadre	0.65	3.01	1.96
CLPT ClearPoint Neuro	N/A	4.54	3.61
LQDA Liquidia	N/A	6.33	6.33

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AORT Artivion	86.37%
CDRE Cadre	43.95%
CLPT ClearPoint Neuro	30.08%
LQDA Liquidia	64.54%

Insider Ownership

Company	Insider Ownership
AORT Artivion	7.60%
CDRE Cadre	37.00%
CLPT ClearPoint Neuro	6.97%
LQDA Liquidia	26.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AORT Artivion	1,300	42.70 million	38.52 million	Optionable
CDRE Cadre	2,240	40.66 million	25.58 million	Optionable
CLPT ClearPoint Neuro	110	27.99 million	25.90 million	Optionable
LQDA Liquidia	50	85.49 million	59.16 million	Optionable

CLPT, LQDA, CDRE, and AORT Headlines

Recent News About These Companies

FDA Approves Liquidia Corporation (LQDA)’s YUTREPIA Amid Patent Dispute

May 24 at 6:38 PM | msn.com

Liquidia (NASDAQ:LQDA) Upgraded at Wall Street Zen

May 24 at 12:00 PM | marketbeat.com

Drugmaker on verge of multibillion-dollar market

May 23 at 7:16 PM | bizjournals.com

U.S. FDA Approves Liquidia's YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

May 23 at 2:28 PM | globenewswire.com

Liquidia's (LQDA) Buy Rating Reaffirmed at Needham & Company LLC

May 23 at 8:28 AM | marketbeat.com

BNP Paribas Financial Markets Sells 53,308 Shares of Liquidia Co. (NASDAQ:LQDA)

May 23 at 3:17 AM | marketbeat.com

Liquidia Co. (NASDAQ:LQDA) Holdings Increased by Whitefort Capital Management LP

May 22 at 6:26 AM | marketbeat.com

Northern Trust Corp Purchases 96,381 Shares of Liquidia Co. (NASDAQ:LQDA)

May 22 at 3:06 AM | marketbeat.com

Vestal Point Capital LP Buys 260,000 Shares of Liquidia Co. (NASDAQ:LQDA)

May 21, 2025 | marketbeat.com

Oppenheimer Downgrades Liquidia (LQDA)

May 20, 2025 | msn.com

Tang Capital Management LLC Buys 300,000 Shares of Liquidia Co. (NASDAQ:LQDA)

May 20, 2025 | marketbeat.com

Janus Henderson Group PLC Has $6.29 Million Stock Position in Liquidia Co. (NASDAQ:LQDA)

May 20, 2025 | marketbeat.com

Liquidia Co. (NASDAQ:LQDA) Shares Acquired by Focus Partners Wealth

May 20, 2025 | marketbeat.com

Liquidia (NASDAQ:LQDA) Downgraded to "Underperform" Rating by Oppenheimer

May 20, 2025 | americanbankingnews.com

Liquidia Co. (NASDAQ:LQDA) Receives Average Rating of "Buy" from Analysts

May 18, 2025 | marketbeat.com

Liquidia (NASDAQ:LQDA) Reaches New 52-Week High - Time to Buy?

May 17, 2025 | marketbeat.com

HC Wainwright Estimates Liquidia's Q2 Earnings (NASDAQ:LQDA)

May 17, 2025 | americanbankingnews.com

Liquidia Co. (NASDAQ:LQDA) is Patient Square Capital LP's 2nd Largest Position

May 16, 2025 | marketbeat.com

Why Liquidia Corporation’s (LQDA) Stock Is Up 6.66%

May 15, 2025 | aaii.com

Maven Securities LTD Sells 100,000 Shares of Liquidia Co. (NASDAQ:LQDA)

May 15, 2025 | marketbeat.com

Raymond James Financial Inc. Takes Position in Liquidia Co. (NASDAQ:LQDA)

May 15, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLPT, LQDA, CDRE, and AORT Company Descriptions

Artivion NYSE:AORT

$28.64 +0.18 (+0.63%)

Closing price 05/23/2025 03:59 PM Eastern

Extended Trading

$28.62 -0.03 (-0.09%)

As of 05/23/2025 04:04 PM Eastern

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.

Cadre NYSE:CDRE

$32.69 -0.44 (-1.33%)

Closing price 05/23/2025 03:59 PM Eastern

Extended Trading

$32.70 +0.01 (+0.02%)

As of 05/23/2025 06:13 PM Eastern

Cadre Holdings, Inc. manufactures and distributes safety that provides protection to users in hazardous or life-threatening situations in the United States and internationally. The company operates in two segments, Products and Distribution. It offers body armor product, such as concealable, corrections, and tactical armor under the Safariland and Protech Tactical brand names; survival suits, remotely operated vehicles, specialty tools, blast sensors, accessories, and vehicle blast attenuation seats for bomb safety technicians; bomb suits; duty gear, including belts and accessories; and other protective equipment comprising communications gear, forensic and investigation products, firearms cleaning solutions, and crowd control products. The company also offers third-party products, such as uniforms, optics, boots, firearms, and ammunition. It serves first responders, such as state and local law enforcement, fire and rescue, explosive ordnance disposal technicians, emergency medical technicians, fishing, and wildlife enforcement and departments of corrections, as well as federal agencies including the U.S. Department of State, U.S. Department of Defense, U.S. Department of Interior, U.S. Department of Justice, U.S. Department of Homeland Security, U.S. Department of Corrections, the Department of Energy, Los Alamos National Laboratories, Waste Isolation Plant, and various foreign government agencies. Cadre Holdings, Inc. was founded in 1964 and is headquartered in Jacksonville, Florida.

ClearPoint Neuro NASDAQ:CLPT

$11.89 -0.19 (-1.57%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$11.90 +0.01 (+0.08%)

As of 05/23/2025 07:43 PM Eastern

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.

Liquidia NASDAQ:LQDA

$15.35 -0.21 (-1.35%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$15.68 +0.34 (+2.18%)

As of 05/23/2025 07:59 PM Eastern

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time